People with autosomal dominant polycystic kidney disease (ADPKD) are at a high risk of developing kidney failure during their lives. Although there are many strategies that can be used to help reduce ...

In 2002, Nicole Harr was diagnosed with polycystic kidney disease, or PKD, the same illness that had caused her father's health to steadily decline until he died of a heart attack. She was 35 with two ...

Add Yahoo as a preferred source to see more of our stories on Google. Sep. 3—(StatePoint) This article is sponsored by Otsuka America Pharmaceutical, Inc. Each year, September 4 marks Polycystic ...

Otsuka wants to create a next generation of kidney disease patients—Gen J. Short for Generation J, with the J standing for Jynarque, they're the first age group who may be able to control progression ...

Lupin has received tentative approval from the Food and Drug Administration for Tolvaptan tablets, 15 mg, 30 mg, 45 mg, 60 mg and 90 mg, which is a generic of Otsuka Pharmaceutical’s Jynarque tablets.

Lupin is rolling out tolvaptan tablets, 15 mg, 30 mg, 45 mg, 60 mg and 90 mg in the United States. Lupin holds the exclusive first-to-file status for this product and will have 180-day generic drug ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Jynarque as the first treatment in the U.S. for adult patients with rapidly progressing ...

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the U.S. Food and Drug Administration (FDA) has approved JYNARQUE ™ (tolvaptan) as the first drug treatment to slow kidney function decline in ...

(StatePoint) This article is sponsored by Otsuka America Pharmaceutical, Inc. Each year, September 4 marks Polycystic Kidney Disease (PKD) Awareness Day, an initiative that aims to increase public ...